Gembloux, Belgium – August 20, 2026 – Full-Life Technologies (“Full-Life”, the “Company”), a fully integrated clinical-stage global radiotherapeutics company, today announced the completion of construction of its state-of-the-art manufacturing facility in Gembloux, Belgium, and the receipt of authorization to begin the commissioning and initial ramp-up phase of the facility’s accelerator

The milestone marks an important step toward bringing Full-Life’s vertically integrated radioisotope manufacturing capabilities into operation. With construction of the facility now completed, the Company has entered the next phase of operational readiness, including progressive commissioning of the accelerator and verification of key safety and operating systems.

The commissioning program will involve a phased ramp-up of the accelerator, together with a series of technical and safety assessments designed to confirm the performance of critical systems prior to routine operation. These activities represent an important transition from facility construction to operational qualification and ultimately to the production of radioisotopes for radiopharmaceutical development and manufacturing.

“The completion of construction and the start of accelerator commissioning represent a major milestone for Full-Life,” said Philippe van Put, General Manager of Full-Life Technology Europe. “Over the past several years, we have built this facility from the ground up with the objective of creating a reliable, scalable and integrated source of radioisotopes for our radiopharmaceutical programs. Entering the commissioning phase brings us one step closer to establishing in-house production capabilities that can support both our clinical pipeline and, ultimately, patients globally.”

Full-Life’s Belgium facility is a key component of the Company’s strategy to establish an integrated global radiopharmaceutical platform spanning research and development, isotope production, manufacturing and commercialization. The facility is designed to strengthen Full-Life’s control over radioisotope supply, including actinium-225 (²²⁵Ac), and to support the continued advancement of the growing radiotherapeutics pipeline.

About Full-Life Technologies

Full-Life Technologies ("Full-Life") is a privately held, fully integrated clinical-stage global radiotherapeutics company with operations worldwide. The Company's mission is to bring the power of radiotherapy to cancer patients globally through an integrated model spanning radiopharmaceutical research and development, production and commercialization. By combining advanced manufacturing capabilities, biological insights and clinical efficiency, Full-Life works to address fundamental challenges in radiopharmaceuticals through pioneering research focused on future cancer treatments. The Company is led by fast-moving entrepreneurs and seasoned scientists with strong life sciences experience and a patient-centered focus.

Media Contacts:

Full-Life

Email: pr@t-full.com

Website: www.full-life.com